13 February 2009--Biota Holdings Limited today reported that it had received revised advice from GlaxoSmithKline regarding Relenza sales for the December 2008 quarter. The revised sales were $27.1 million ($20.8 million) and indicative royalties were $1.9 million ($1.46 million). This revision represents an additional $0.44 million in royalties to Biota.
The details can be read here.
No comments:
Post a Comment